Search Results - "Collisson, Eric Andrew"

Blockchain-authenticated sharing of cancer patient genomic and clinical outcomes data by Burns, Shohei, Collisson, Eric Andrew

“…Abstract only e19358 Background: Efficiently sharing health data produced during standard care could dramatically accelerate progress in cancer treatments but…”
Get full text

Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States by Klein-Brill, Avital, Amar-Farkash, Shlomit, Lawrence, Gabriella, Collisson, Eric Andrew, Fisch, Michael Jordan, Aran, Dvir

“…e16271 Background: The common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC) are FOLFIRINOX and gemcitabine plus nab-paclitaxel…”
Get full text

Optimizing pancreatic cancer management with next generation imaging and liquid biopsy (CHANGE-PDAC) by Tsang, Erica S, Collisson, Eric Andrew, Wang, Zhen J., Piawah, Sorbarikor, Sanchez, Taylor, Tempero, Margaret A., Ko, Andrew H.

“…Abstract only TPS640 Background: Pancreatic ductal adenocarcinoma (PDAC) is anticipated to become the second-leading cause of cancer-related deaths by 2030…”
Get full text

The marginal diagnostic benefit of pancreatic cancer molecular profiling after germline testing by Walker, Evan Justin, Blanco, Amie, Carnevale, Julia C., Cinar, Pelin, Collisson, Eric Andrew, Tempero, Margaret A., Ko, Andrew H.

“…Abstract only 10513 Background: Germline genetic testing is now universally recommended for patients (pts) with pancreatic ductal adenocarcinoma (PDAC) for…”
Get full text

Alliance A022106: A phase II/III trial of NABPLAGEM vs nab-paclitaxel/gemcitabine as second-line treatment for BRCA1/2 or PALB2 mutant metastatic pancreatic ductal adenocarcinoma (PLATINUM) by Tsang, Erica S, Shi, Qian, Olive, Kenneth P., Collisson, Eric Andrew, Dixon, Jesse G., Cusnir, Mike, Winograd, Rafael, Botta, Gregory P., Wadlow, Raymond Couric, Shergill, Ardaman, Meyerhardt, Jeffrey A., O'Reilly, Eileen M., Ko, Andrew H.

“…TPS4205 Background: Multiple lines of evidence support the use of platinum-based chemotherapy for patients with homologous recombination deficiency-associated…”
Get full text

Development of artificial intelligence–derived histological biomarkers for first-line treatment selection in metastatic pancreatic ductal adenocarcinoma (mPDAC) by Krishna, Viswesh, Tiu, Ekin, Krishna, Vrishab, Vrabac, Damir, Shah, Kunal, Abuzeid, Waleed, Smith, Katelyn, Davelaar, John, Nuesca, Christopher, Larson, Brent K, Fountzilas, Christos, Rajpurkar, Pranav, Hendifar, Andrew Eugene, Collisson, Eric Andrew, Joshi, Anirudh, Singhi, Aatur D.

“…743 Background: The prognosis of metastatic pancreatic ductal adenocarcinoma (mPDAC) remains poor with a median survival time of 10-12 months. First-line…”
Get full text

Investigating tumor molecular profiling as a possible contributor to racial/ethnic disparities in pancreatic cancer by Walker, Evan Justin, Piawah, Sorbarikor, Griffin, Ann, Carnevale, Julia C., Cinar, Pelin, Collisson, Eric Andrew, Tempero, Margaret A., Ko, Andrew H.

“…Abstract only 6522 Background: A variety of biologic, socioeconomic, and treatment-related factors may contribute to the racial/ethnic disparities observed in…”
Get full text

Gemcitabine response prediction in the adjuvant treatment of resected pancreatic ductal adenocarcinoma using an AI histopathology platform by Krishna, Viswesh, Nimgaonkar, Vivek, Tiu, Ekin, Krishna, Vrishab, Bhambhvani, Hriday, Cook, Stephen, Miller, Daniel, Vrabac, Damir, Joshi, Anirudh, Singhi, Aatur D., Hendifar, Andrew Eugene, Rajpurkar, Pranav, Collisson, Eric Andrew

“…e16295 Background: Adjuvant chemotherapy improves survival following resection of pancreatic ductal adenocarcinoma (PDAC). A modified…”
Get full text

Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC) by Picozzi, Vincent J., Duliege, Anne-Marie, Collisson, Eric Andrew, Maitra, Anirban, Hidalgo, Manuel, Hendifar, Andrew Eugene, Beatty, Gregory Lawrence, Doss, Sudheer, Matrisian, Lynn McCormick, Herena, Pamela S, Fleshman, Julie, Detry, Michelle A., Berry, Donald A., Simeone, Diane M.

“…TPS4188 Background: The success rate of drug development in PDAC is disappointingly low.PrP is a transformative, adaptive platform clinical trial designed to…”
Get full text

Characteristics and growth rate of lung metastases in patients with primary gastrointestinal malignancies: A retrospective cohort analysis by Burns, Shohei, Vella, Maya, Paciorek, Alan, Zhang, Li, Atreya, Chloe Evelyn, Collisson, Eric Andrew, Feng, Mary Uan-Sian, Kelley, Robin Kate, Tempero, Margaret A., Van Loon, Katherine, Ko, Andrew H.

“…Abstract only 442 Background: There are no formal guidelines for the management of GI cancer pts with lung-exclusive or lung-predominant metastases (LM), which…”
Get full text

Referral patterns and attrition rate for germline testing in pancreatic cancer (PC) patients by Walker, Evan Justin, Carnevale, Julia C., Pedley, Christina, Blanco, Amie, Chan, Salina, Collisson, Eric Andrew, Ko, Andrew H.

“…Abstract only…”
Get full text

Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) by Bocobo, Andrea Grace, Wang, Renee, Behr, Spencer, Carnevale, Julia C., Cinar, Pelin, Collisson, Eric Andrew, Fong, Lawrence, Keenan, Bridget P, Kidder, Wesley Allen, Ko, Andrew H., Kolli, Kanti Pallav, Kennedy, Megan, Laffan, Angela, Piawah, Sorbarikor, Pollak, Marin, Schwartz, Gabriel, Whitman, Julia, Zhang, Li, Van Loon, Katherine, Atreya, Chloe Evelyn

“…3565 Background: MSS mCRC rarely responds to pembrolizumab monotherapy, but capecitabine and bevacizumab may induce immune-stimulatory effects. This study…”
Get full text

Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas by Katz, Matthew H. G., Shi, Qian, Meyers, Jeffrey P., Herman, Joseph M., Choung, Michael, Wolpin, Brian M., Ahmad, Syed, Marsh, Robert de Wilton, Schwartz, Lawrence Howard, Behr, Spencer, Frankel, Wendy L., Collisson, Eric Andrew, Leenstra, James Lewis, Williams, Terence Marques, Vaccaro, Gina M., Venook, Alan P., Meyerhardt, Jeffrey A, O'Reilly, Eileen Mary

“…Abstract only 377 Background: Neoadjuvant therapy has been associated with a median overall survival (OS) of 18 – 23 months (mo) in patients (pts) with BR…”
Get full text

Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis by Bocobo, Andrea Grace, Wang, Renee, Behr, Spencer, Carnevale, Julia C., Cinar, Pelin, Collisson, Eric Andrew, Fong, Lawrence, Kidder, Wesley Allen, Ko, Andrew H., Kolli, Kanti Pallav, Kennedy, Megan, Laffan, Angela, Lindsay, Sheila, Nalla, Sneha, Schwartz, Gabriel, Whitman, Julia, Zendejas, Patricia, Zhang, Li, Van Loon, Katherine, Atreya, Chloe Evelyn

“…Abstract only 77 Background: MSS mCRC rarely responds to pembrolizumab monotherapy, but capecitabine and bevacizumab may induce immune-stimulatory effects…”
Get full text

Concurrent genomic alterations in lung adenocarcinoma with a MET exon 14 skipping mutation by Rotow, Julia, Wu, Wei, Blakely, Collin M., Lanman, Richard B., Raymond, Victoria M., Kaye, Frederic J., Gui, Phillipe, Fraser, James, Wolff, Alexander, Collisson, Eric Andrew, McCoach, Caroline Elizabeth, Bivona, Trever Grant

“…Abstract only…”
Get full text

Quantification of tumor stroma as a biomarker in pancreatic adenocarcinoma by Torphy, Robert J., Volmar, Keith E., Naim, Rashid, Cader, Sonia Rosanne, Johansen, Julia S., Hollingsworth, Michael A., Collisson, Eric Andrew, Yeh, Jen Jen

“…Abstract only…”
Get full text

Comparative circulating tumor DNA levels for KRAS mutations in patients with nonresectable pancreatic cancer by Johansen, Julia S., Vibat, Cecile Rose T., Calatayud, Dan, Jensen, Benny Vittrup, Hasselby, Jane Preuss, Collisson, Eric Andrew, Lu, Timothy, Poole, Jason C., Erlander, Mark

“…Abstract only 288 Background: Non-resectable pancreatic cancer patients have a wide range of median time for overall survival (OS). Currently there is a lack…”
Get full text

Prognostic value of plasma circulating tumor (ct) DNA KRAS mutations and serum CA19-9 in unresectable pancreatic cancer (PC) patients by Johansen, Julia S., Vibat, Cecile Rose T., Hancock, Saege, Chen, Inna Markovna, Hassaine, Latifa, Samuelsz, Errin, Collisson, Eric Andrew, Jensen, Benny Vittrup, Lu, Timothy T., Melnikova, Vlada, Erlander, Mark G.

“…Abstract only…”
Get full text

Prospective evaluation of circulating tumor DNA sequencing in pancreatobiliary carcinomas by Collisson, Eric Andrew, Zill, Oliver, Greene, Claire, Leng, Jim, Siew, LaiMun, Vu, Mary A., Kelley, Robin Kate, Ko, Andrew H., Atreya, Chloe Evelyn, Van Loon, Katherine, Bivona, Trever Grant, Tempero, Margaret A., Sebisanovic, Dragan, Munster, Pamela N., Talasaz, AmirAli

“…Abstract only…”
Get full text

Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101 by Katz, Matthew H. G., Shi, Qian, Ahmad, Syed A., Herman, Joseph M., Marsh, Robert de Wilton, Collisson, Eric Andrew, Schwartz, Lawrence H., Martin, Robert C. G., Conway, William Charles, Truty, Mark, Kindler, Hedy Lee, Lowy, Andrew M., Philip, Philip Agop, Bekaii-Saab, Tanios S., Cardin, Dana Backlund, LoConte, Noelle K., Venook, Alan P.

“…Abstract only…”
Get full text